Frank Brennan
Head of Immune Reset UCB
Seminars
Thursday 10th September 2026
What can be Improved Upon for Existing Drugs?
8:45 am
- Discussing approaches to differentiate assets targeting competitive targets
- With clinical data so far, what constitutes a good outcome in autoimmune disease and which approach gets you there?
- Protocol design to define initial target indications, strategizing how to rapidly generate early clinical, proof-of-concept data, and differentiating company assets within competitive landscapes
Wednesday 9th September 2026
Scientific, Operational & Economic Realities for Immune-Modulating Therapies: What Have we Learnt so Far?
11:40 am
- Pharma’s reflections on recent in vivo CAR-T deals, what data was valuable when clinical data was minimal?
- Overlapping and diverging advantages of TCEs to in vivo CAR-T, including depth and durability of response.
- Debating clinical-adjacent innovations in delivery across viral vectors and LNPs and their application in immunology versus oncology
